Cardiovascular & General; Cardiovascular & Metabolic

C-Type Natriuretic Peptide (CNP)

C-type natriuretic peptide belongs to a family of heart-and-vessel hormones, but it does its most consequential work somewhere unexpected: the growth plates, the bands of cartilage at the ends of a child's bones where new length is added. That is where the clinical interest went. Chemical analogues of it, principally vosoritide, have been studied in children with achondroplasia and hypochondroplasia, the commonest inherited causes of restricted bone growth, and a meta-analysis of those analogues is on file. The natural peptide itself has only been given to people in small physiology studies, including one infusing it into the forearm; no trial on file uses it as a treatment.

Last updated 12 August 2026

Studied forEndochondral bone growth research · Vascular tone research · Short stature research context

Evidence on file1 randomised human trial · 2 human observational studies · 4 animal studies · 1 citation not yet graded

Strongest sourceEffect of Vosoritide Therapy on IGF-I and Endogenous C-Type Natriuretic Peptide in Hypochondroplasia. (randomised human trial)

Mechanism

Binds natriuretic peptide receptor-B, a guanylyl cyclase, raising cGMP and PKGII activity in growth-plate chondrocytes.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

Endochondral bone growth research
Vascular tone research
Short stature research context

Dosing on file unverified

10 pmol/kg/min infusion; 0.43 nmol/kg single dose (Phase I/II research); 0.43 nmol/kg single dose; Phase I/II research only

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Half-life, storage & sport

Elimination half-life: 2.6 minutes (human, IV) — study. JCI insight 2026.

The half-life on file is 3 min, measured intravenously. No dosing schedule could be read from this record, so the curve below is one dose drawn from the moment it is given. Nothing here says how often it is repeated.

One dose. 13 min of decay, normalised to its own peak.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Literature on file 8

animal in vivo
Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide (1992, cited 585x) graded on: an animal model — read from the indexed abstract — “rats”
human RCT
Effect of Vosoritide Therapy on IGF-I and Endogenous C-Type Natriuretic Peptide in Hypochondroplasia. graded on: a phase 2 trial — read from the indexed abstract — “phase 2 clinical trial”
human observational
Achondroplasia management in the era of targeted therapies: a meta-analysis of C-type natriuretic peptide analogs. graded on: a synthesis of human studies — “meta-analysis”
animal in vivo
Combined treatment with a C-type natriuretic peptide analog and bisphosphonate enhances bone growth in growing mice with osteogenesis imperfecta: a pilot study. graded on: an animal model — “mice”
animal in vivo
Supplementation with C-type natriuretic peptide during pre-in vitro maturation regulates key aspects of cumulus cell physiology in cattle. graded on: an animal model — “cattle”
animal in vivo
C-type natriuretic peptide pre-maturation culture affects cytoplasmic maturation in bovine oocytes†. graded on: an animal model — “bovine”
human observational
NCT04006171: C Type Natriuretic Peptide and Polycystic Ovary Syndrome graded on: a registered clinical study — “clinicaltrials.gov”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

not graded
NCT01075776: The Effects of C-type Natriuretic Peptide on Endothelial Function Following Ischaemia-Reperfusion in the Human Forearm graded on: NCT01075776 is withdrawn and has posted no results - a registration, not a reported outcome — “NCT01075776”

Identity

Space-filling 3D model of C-Type Natriuretic Peptide (CNP), carbon grey, nitrogen blue, oxygen red — Built from the SMILES on this record — the atoms and bonds are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation, and where the SMILES leaves a stereocentre undefined the pose commits to one arbitrarily. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

2D chemical structure of C-Type Natriuretic Peptide (CNP) — Built from the SMILES on this record — the atoms and bonds are exact. The shape is **one computed low-energy pose**, not a measured structure: a flexible peptide in solution has no single conformation, and where the SMILES leaves a stereocentre undefined the pose commits to one arbitrarily. The skeletal formula below claims connectivity and nothing more, which is what we actually know.

Molecular weight: 2197.6
Molecular formula: C93H157N27O28S3
CAS number: 127869-51-6
PubChem CID: 16179407
UniProt: P23582 (precursor)
InChI key: UHSBKBYWHCBDCJ-DYGWFTAGSA-N
SMILES: CC[C@H](C)[C@H]1C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CN)C(=O)O)CC(C)C)CO)CCSC)CO
InChI: InChI=1S/C93H157N27O28S3/c1-12-52(10)76-91(146)104-42-72(127)108-65(44-122)88(143)114-57(26-30-149-11)82(137)118-64(43-121)80(135)103-39-70(125)106-58(31-48(2)3)78(133)101-41-74(129)110-68(92(147)148)47-151-150-46-67(109-73(128)40-100-77(132)54(23-16-18-27-94)111-89(144)66(45-123)119-85(140)59(32-49(4)5)105-69(124)37-96)90(145)116-62(35-53-21-14-13-15-22-53)79(134)102-38-71(126)107-60(33-50(6)7)84(139)112-55(24-17-19-28-95)81(136)115-61(34-51(8)9)86(141)117-63(36-75(130)131)87(142)113-56(83(138)120-76)25-20-29-99-93(97)98/h13-15,21-22,48-52,54-68,76,121-123H,12,16-20,23-47,94-96H2,1-11H3,(H,100,132)(H,101,133)(H,102,134)(H,103,135)(H,104,146)(H,105,124)(H,106,125)(H,107,126)(H,108,127)(H,109,128)(H,110,129)(H,111,144)(H,112,139)(H,113,142)(H,114,143)(H,115,136)(H,116,145)(H,117,141)(H,118,137)(H,119,140)(H,120,138)(H,130,131)(H,147,148)(H4,97,98,99)/t52-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,76-/m0/s1

Also called

CNP (C-Type Natriuretic Peptide)

Notes unverified prose

Human studies:; Human IV infusion studies

Not on file 1

1 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

amino-acid sequencenothing we hold supplies it

Each field links to every other record missing the same thing. The full ledger holds 765 gaps across 163 records.

At a glance

Strongest rung: human RCT
Citations: 8
Regulatory: Human research reported (unverified)
Route: Intravenous
Declared gaps: 1

Citations by rung

Strongest wins, never an average.